Alessandro Ottaiano

Summary

Country: Italy

Publications

  1. ncbi request reprint Biological prognostic factors in adult soft tissue sarcomas
    Alessandro Ottaiano
    Division of Immunology, National Cancer Institute, G Pascale Foundation, Via Mariano Semmola, 80131, Naples, Italy
    Anticancer Res 25:4519-26. 2005
  2. ncbi request reprint Prospective clinical trials of biotherapies in solid tumors: a 5-year survey
    Alessandro Ottaiano
    Department of Medical Oncology, ULSS2, Santa Maria del Prato Hospital, via Bagnols Ceze, Feltre BL, Italy
    Cancer Immunol Immunother 54:44-50. 2005
  3. ncbi request reprint Evidence of publication bias in clinical trials of biotherapies for solid tumors
    Alessandro Ottaiano
    Division of Clinical Immunology, National Cancer Institute, Naples, Italy
    Cancer 103:653. 2005
  4. ncbi request reprint Inhibitory effects of anti-CXCR4 antibodies on human colon cancer cells
    Alessandro Ottaiano
    Division of Clinical Immunology, National Cancer Institute, Via M Semmola, 80131 Naples, Italy
    Cancer Immunol Immunother 54:781-91. 2005
  5. ncbi request reprint Prognostic value of CD40 in adult soft tissue sarcomas
    Alessandro Ottaiano
    Division of Medical Oncology B, National Cancer Institute, Naples, Italy
    Clin Cancer Res 10:2824-31. 2004
  6. ncbi request reprint Expression of CD40 has no predictive value in soft tissue sarcomas
    A Ottaiano
    Department of Medical Oncology B, National Cancer Institute, G Pascale, Via M Semmola, 80131, Naples, Italy
    Anticancer Res 23:1597-604. 2003
  7. ncbi request reprint Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients
    Alessandro Ottaiano
    Department of Clinical Immunology, National Cancer Institute, G Pascale Foundation, Naples, Italy
    Clin Cancer Res 12:2795-803. 2006
  8. ncbi request reprint Neoadjuvant chemotherapy for intermediate/high-grade soft tissue sarcomas: five-year results with epirubicin and ifosfamide
    A Ottaiano
    Department of Medical Oncology B, Division of Medical Oncology B, National Cancer Institute, G Pascale, Via M Semmola, 80131, Naples, Italy
    Anticancer Res 22:3555-9. 2002
  9. ncbi request reprint CD40 activation as potential tool in malignant neoplasms
    Alessandro Ottaiano
    Division of Medical Oncology B, National Cancer Institute G Pascale, Naples, Italy
    Tumori 88:361-6. 2002
  10. ncbi request reprint Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma
    Stefania Scala
    Department of Clinical Immunology, National Cancer Institute, G Pascale Foundation, Via Mariano Semmola, 80131 Naples, Italy
    Clin Cancer Res 11:1835-41. 2005

Collaborators

Detail Information

Publications32

  1. ncbi request reprint Biological prognostic factors in adult soft tissue sarcomas
    Alessandro Ottaiano
    Division of Immunology, National Cancer Institute, G Pascale Foundation, Via Mariano Semmola, 80131, Naples, Italy
    Anticancer Res 25:4519-26. 2005
    ..In the present survey, we focused on the role of new biological prognostic factors in STSs and also reported the quality of such studies with an ad hoc designed questionnaire...
  2. ncbi request reprint Prospective clinical trials of biotherapies in solid tumors: a 5-year survey
    Alessandro Ottaiano
    Department of Medical Oncology, ULSS2, Santa Maria del Prato Hospital, via Bagnols Ceze, Feltre BL, Italy
    Cancer Immunol Immunother 54:44-50. 2005
    ..To review the content and quality of prospective clinical trials of biotherapies in solid tumors...
  3. ncbi request reprint Evidence of publication bias in clinical trials of biotherapies for solid tumors
    Alessandro Ottaiano
    Division of Clinical Immunology, National Cancer Institute, Naples, Italy
    Cancer 103:653. 2005
  4. ncbi request reprint Inhibitory effects of anti-CXCR4 antibodies on human colon cancer cells
    Alessandro Ottaiano
    Division of Clinical Immunology, National Cancer Institute, Via M Semmola, 80131 Naples, Italy
    Cancer Immunol Immunother 54:781-91. 2005
    ..CXCR4, the chemokine receptor for CXCL12, has recently been involved in the metastatic process of several neoplasms...
  5. ncbi request reprint Prognostic value of CD40 in adult soft tissue sarcomas
    Alessandro Ottaiano
    Division of Medical Oncology B, National Cancer Institute, Naples, Italy
    Clin Cancer Res 10:2824-31. 2004
    ..The purpose is to evaluate the expression of CD40, a membrane protein predominantly expressed on B cells, dendritic cells, and macrophages, in a series of adult soft tissue sarcomas and to test its possible prognostic value...
  6. ncbi request reprint Expression of CD40 has no predictive value in soft tissue sarcomas
    A Ottaiano
    Department of Medical Oncology B, National Cancer Institute, G Pascale, Via M Semmola, 80131, Naples, Italy
    Anticancer Res 23:1597-604. 2003
    ..The present study was undertaken to determine if there is a correlation between the expression of CD40 in spindle-cell sarcomas and the response to epirubicin and ifosfamide chemotherapy...
  7. ncbi request reprint Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients
    Alessandro Ottaiano
    Department of Clinical Immunology, National Cancer Institute, G Pascale Foundation, Naples, Italy
    Clin Cancer Res 12:2795-803. 2006
    ....
  8. ncbi request reprint Neoadjuvant chemotherapy for intermediate/high-grade soft tissue sarcomas: five-year results with epirubicin and ifosfamide
    A Ottaiano
    Department of Medical Oncology B, Division of Medical Oncology B, National Cancer Institute, G Pascale, Via M Semmola, 80131, Naples, Italy
    Anticancer Res 22:3555-9. 2002
    ..However its role as induction therapy before surgery should still be proved...
  9. ncbi request reprint CD40 activation as potential tool in malignant neoplasms
    Alessandro Ottaiano
    Division of Medical Oncology B, National Cancer Institute G Pascale, Naples, Italy
    Tumori 88:361-6. 2002
    ..The general aim of this review is to focus the attention of clinical oncologists on the involvement of CD40 in tumors and the rationale of CD40-activation-based therapies in new, biologically oriented antitumor protocols...
  10. ncbi request reprint Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma
    Stefania Scala
    Department of Clinical Immunology, National Cancer Institute, G Pascale Foundation, Via Mariano Semmola, 80131 Naples, Italy
    Clin Cancer Res 11:1835-41. 2005
    ..Evidence about the role of CXCR4/CXCL12 axis has been reported in several cancers including melanoma. Our goal was to investigate if CXCR4 expression has a prognostic value in malignant melanoma...
  11. doi request reprint CD4(+)CD45RA(+)CXCR4 (+) lymphocytes are inversely associated with progression in stages I-III melanoma patients
    Maria Napolitano
    Department of Clinical Immunology, National Cancer Institute, G Pascale Foundation, Via Mariano Semmola, 80131 Naples, Italy
    Cancer Immunol Immunother 59:511-7. 2010
    ....
  12. ncbi request reprint Human melanoma metastases express functional CXCR4
    Stefania Scala
    Department of Clinical Immunology, National Cancer Institute, G Pascale Foundation, Naples, Italy
    Clin Cancer Res 12:2427-33. 2006
    ..The chemokine receptor CXCR4 was identified as an independent predictor of poor prognosis in primary melanoma. The aim of the study was to investigate the role of CXCR4 in human melanoma metastases...
  13. ncbi request reprint CXC chemokine receptor 4 is expressed in uveal malignant melanoma and correlates with the epithelioid-mixed cell type
    Stefania Scala
    Department of Clinical Immunology, National Cancer Institute, G Pascale Foundation, Via Mariano Semmola, 80131, Naples, Italy
    Cancer Immunol Immunother 56:1589-95. 2007
    ..CXCR4, a chemokine receptor, is a prognostic factor in cutaneous melanoma involved in angiogenesis and metastasis formation. The aim of this study was to evaluate the expression of CXCR4 in uveal melanoma...
  14. ncbi request reprint Statistical design in phase II clinical trials and its application in breast cancer
    Francesco Perrone
    Clinical Trials Unit, National Cancer Institute, Naples, Italy
    Lancet Oncol 4:305-11. 2003
    ..15) were independently predictive of the presence of statistical design. Publication in journals with high impact factors and short intervals between the start of the study and publication were also correlated with statistical design...
  15. ncbi request reprint Temozolomide and cisplatin in avdanced malignant melanoma
    Antonio Daponte
    National Tumor Institute Via M Semmola, 80131 Naples, Italy
    Anticancer Res 25:1441-7. 2005
    ..On the basis of these results, we designed a phase II study to evaluate the activity and safety profile of the TMZ-CDDP association in patients with advanced melanoma...
  16. ncbi request reprint Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies
    Paolo A Ascierto
    Pascale NAtional Cancer Institute, Naples, Italy
    J Clin Oncol 23:7660-8. 2005
    ..A novel amino acid-degrading enzyme (arginine deiminase) conjugated to polyethylene glycol (ADI-SS PEG 20,000 mw) was used to lower plasma arginine in individuals with metastatic melanoma...
  17. ncbi request reprint Soluble interleukin-2 receptor in stage I-III melanoma
    Alessandro Ottaiano
    Division of Clinical Immunology, National Cancer Institute of Naples, G Pascale Foundation, Via Mariano Semmola, 80131 Naples, Italy
    Cytokine 33:150-5. 2006
    ..5% compared to 87% for patients with no sIL-2R values>600 U/ml during follow-up. sIL-2R values are associated with progression of MM. Further studies are needed to address the role of the IL-2/IL-2R/sIL-2R axis in melanoma biology...
  18. ncbi request reprint Pancreatic involvement from heavily pretreated small cell lung cancer successfully treated with transcatheter intra-arterial chemotherapy: a case report with local and systemic disease control
    Alessandro Ottaiano
    Division of Medical Oncology B, National Cancer Institute, Naples, Italy
    Tumori 88:535-7. 2002
    ....
  19. ncbi request reprint Concomitant occurrence of facial cutaneous and parotid gland metastases from rectal cancer after preoperative chemoradiotherapy
    Guglielmo Nasti
    B Medical Oncology, National Institute of Tumours Fondazione G Pascale, Naples, Italy
    Onkologie 30:324-6. 2007
    ..Unusual sites of metastasis to the parotid gland and face are reported in patients with colorectal cancer, but the localization to both sites at the same time has never been described so far...
  20. ncbi request reprint Target-based agents in neoadjuvant treatment of liver metastases from colorectal cancer: secret weapons in anti-cancer war?
    Monica Marra
    Department of Biochemistry and Biophysics, Second University of Naples, Naples, Italy
    Cancer Biol Ther 8:1709-18. 2009
    ..Finally, biological rationales to optimize the activity of these agents in neoadjuvant setting are discussed...
  21. ncbi request reprint Prognostic value of serum VEGF in melanoma patients: a pilot study
    Paolo Antonio Ascierto
    Division of Clinical Immunology, National Cancer Institute, Via M Semmola, 80131 Naples, Italy
    Anticancer Res 24:4255-8. 2004
    ..Vascular endothelial growth factor (VEGF) is involved in angiogenesis. We investigated the association of VEGF serum levels (pre-treatment and follow-up) with outcome in patients with melanoma...
  22. doi request reprint Early PET/CT scan is more effective than RECIST in predicting outcome of patients with liver metastases from colorectal cancer treated with preoperative chemotherapy plus bevacizumab
    Secondo Lastoria
    Nuclear Medicine Unit, Istituto Nazionale Tumori Fondazione G Pascale IRCCS, Naples, Italy
    J Nucl Med 54:2062-9. 2013
    ..Particularly, early changes in tumor metabolism measured by PET/CT with (18)F-FDG could predict the efficacy of treatment better than standard dimensional Response Evaluation Criteria In Solid Tumors (RECIST) response...
  23. pmc Fc gamma receptor IIIa polymorphisms in advanced colorectal cancer patients correlated with response to anti-EGFR antibodies and clinical outcome
    Rosa Calemma
    Oncological Immunology, National Cancer Institute G, Pascale, Naples, Italy
    J Transl Med 10:232. 2012
    ..The present study investigated the association between single nucleotide polymorphisms of FcγRIIa and FcγRIIIa and clinical outcome in mCRC treated with anti-EGFR antibodies...
  24. ncbi request reprint Cyclooxygenase-2 expression is associated with increased size in human sporadic colorectal adenomas
    Carmela Pisano
    Medical Oncology B, National Cancer Institute, Via Mariano Semmola, 80131, Naples, Italy
    Anticancer Res 25:2065-8. 2005
    ..Cyclooxygenase-2 (COX-2) has been implicated in colorectal carcinogenesis but its role is not completely defined...
  25. ncbi request reprint Survey of modalities of toxicity assessment and reporting in noncomparative prospective studies of chemotherapy in breast cancer
    Francesco Perrone
    Clinical Trials Office, National Cancer Institute, I 80131 Naples, Italy
    J Clin Oncol 20:52-7. 2002
    ..To review how toxicity, a main end point of phase II studies, is assessed and reported in published phase II chemotherapy trials in breast cancer...
  26. ncbi request reprint Adjuvant treatment of malignant melanoma: where are we?
    Paolo A Ascierto
    Unit of Clinical Immunology, Melanoma Cooperative Group, National Cancer Institute, Via Mariano Semmola, 80131 Naples, Italy
    Crit Rev Oncol Hematol 57:45-52. 2006
    ..Conversely, considering the improvement of OS as the main target of MM adjuvant therapy, the "wait and watch" attitude remains the only approach to be pursued at present. It is a physician's choice...
  27. ncbi request reprint Epidermal growth factor receptor as a major anticancer drug target
    Francesco Caponigro
    Istituto Nazionale Tumouri Fondazione G Pascale, Via M Semmola, 80131 Napoli, Italy
    Expert Opin Ther Targets 10:877-88. 2006
    ..Combinations with downstream effectors or other receptor-targeted therapies, or antiangiogenic compounds can be looked at more optimistically as effective weapons...
  28. ncbi request reprint Gastrointestinal non colorectal cancer. Do elderly patients need a specific management?
    Lucrezia Silvestro
    Department of Abdominal Oncology, National Cancer Institute G Pascale Via M Semmola, 80131 Naples, Italy
    Anticancer Agents Med Chem 13:1364-70. 2013
    ..In fact an elderly patient can develop greater toxicity than a younger patient from oncologic treatments (chemotherapy, radiotherapy, target therapies) due to a worse function of vital organs...
  29. ncbi request reprint Second-Line Chemotherapy in Recurrent Clear Cell Ovarian Cancer: Results from the Multicenter Italian Trials in Ovarian Cancer (MITO-9)
    Francesca Esposito
    Istituto Nazionale Tumori Fondazione G Pascale, IRCCS, Naples, Italy
    Oncology 86:351-8. 2014
    ..Data in platinum-resistant patients suggest gemcitabine as the drug with the highest activity. We recommend that gemcitabine be studied prospectively in a phase 2 trial. © 2014 S. Karger AG, Basel. ..
  30. doi request reprint High HMGA2 expression and high body mass index negatively affect the prognosis of patients with ovarian cancer
    Daniela Califano
    Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione Giovanni Pascale, IRCCS, Naples, Italy
    J Cell Physiol 229:53-9. 2014
    ..039). Therefore, the data reported herein suggest that the combined evaluation of HMGA2 expression and obesity assessed through BMI can be considered a marker of poor prognosis in patients affected by ovarian carcinoma...
  31. doi request reprint HMGA1 protein expression in familial breast carcinoma patients
    Gennaro Chiappetta
    Istituto Nazionale dei Tumori, Fondazione Pascale, 80131 Naples, Italy
    Eur J Cancer 46:332-9. 2010
    ..0198). Conversely, no correlation was found between HMGA1 expression and overall survival in patients carrying inherited mutations in the BRCA1 and in BRCAX patients...